Compare Danaher Corporation (DHR) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares China Large-Cap ETF — how do they compare? Danaher Corporation trades at $219.53 (market cap $152.87B), while iShares China Large-Cap ETF trades at $34.15 (market cap $3.86B). The key difference: Danaher Corporation is far larger — about 39.6× iShares China Large-Cap ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares China Large-Cap ETF for 149 Days on average.
| DHR | FXI | |
|---|---|---|
Market Cap | $152.87B | $3.86B |
Volume | 5,228,698 | 16,323,837 |
Sector | Health | — |
52-Week High | $242.05 | $41.08 |
52-Week Low | $161.91 | $31.59 |
Typical Hold Time | 69 Days | 149 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
FXI (iShares China Large-Cap ETF) trades at $34.30, up 2.63% on the day, but technical indicators signal a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges and geopolitical tensions, though some analysts highlight its attractive valuation at half the S&P 500's P/E ratio. Recent news focuses on U.S.-China relations and export dynamics.
The outlook remains cautious due to China's industrial overcapacity and weak domestic consumption. While valuation appears compelling, political risks and technical weakness suggest limited near-term upside. Investors should weigh the discount against ongoing macroeconomic pressures in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
